Erasca Key Executives
This section highlights Erasca's key executives, including their titles and compensation details.
Find Contacts at Erasca
(Showing 0 of )
Erasca Earnings
This section highlights Erasca's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2023 | 2024-03-29 | N/A | N/A |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
$1.38
Stock Price
$389.49M
Market Cap
103
Employees
San Diego, CA
Location
Financial Statements
Access annual & quarterly financial statements for Erasca, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $3.73M | $2.64M | $829.00K | $540.00K |
| Gross Profit | $- | $-3.73M | $-2.64M | $-829.00K | $-540.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $115.36M | $103.82M | $112.46M | $73.92M | $29.55M |
| General and Administrative Expenses | $41.73M | $37.70M | $32.99M | $22.62M | $7.96M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $41.73M | $37.70M | $32.99M | $22.62M | $7.96M |
| Other Expenses | $22.50M | $- | $-257.00K | $1.93M | $7.26M |
| Operating Expenses | $179.59M | $141.53M | $145.45M | $96.54M | $37.51M |
| Cost and Expenses | $- | $141.53M | $145.45M | $96.54M | $37.51M |
| Interest Income | $20.09M | $16.71M | $4.90M | $190.00K | $336.00K |
| Interest Expense | $- | $- | $201.36M | $- | $- |
| Depreciation and Amortization | $- | $3.73M | $2.64M | $829.00K | $540.00K |
| EBITDA | $-179.59M | $-121.31M | $-240.16M | $-121.94M | $-101.12M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-179.59M | $-141.53M | $-247.45M | $-124.88M | $34.24M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $17.94M | $16.48M | $4.64M | $2.12M | $7.59M |
| Income Before Tax | $-161.65M | $-125.04M | $-242.81M | $-122.76M | $-101.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $-4.64M | $27.33M | $71.41M |
| Net Income | $-161.65M | $-125.04M | $-238.16M | $-150.09M | $-173.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.07 | $-0.10 | $-0.24 | $-0.16 | $-0.93 |
| EPS Diluted | $-0.07 | $-0.10 | $-0.24 | $-0.16 | $-0.93 |
| Weighted Average Shares Outstanding | 2.34B | 1.20B | 976.20M | 952.82M | 185.76M |
| Weighted Average Shares Outstanding Diluted | 2.34B | 1.20B | 976.20M | 952.82M | 185.76M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $5.58M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $- | $1.10M | $998.00K | $942.00K | $941.00K | $955.00K | $894.00K | $933.00K | $771.00K | $534.00K | $403.00K | $320.00K | $191.00K | $169.00K | $149.00K | $- | $- | $- | $- |
| Gross Profit | $- | $- | $-1.10M | $-998.00K | $4.64M | $-941.00K | $-955.00K | $-894.00K | $-933.00K | $-771.00K | $-534.00K | $-403.00K | $-320.00K | $-191.00K | $-169.00K | $-149.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 83.10% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $26.12M | $27.63M | $33.03M | $28.57M | $24.80M | $25.21M | $26.22M | $27.59M | $29.36M | $28.18M | $27.49M | $27.43M | $24.13M | $19.95M | $17.60M | $12.24M | $10.06M | $9.07M | $5.86M | $4.55M |
| General and Administrative Expenses | $9.59M | $9.61M | $12.25M | $10.28M | $9.07M | $9.45M | $9.75M | $9.44M | $8.72M | $8.78M | $8.42M | $7.08M | $6.92M | $6.92M | $5.10M | $3.68M | $2.90M | $2.02M | $1.42M | $1.61M |
| Selling and Marketing Expenses | $- | $- | $- | $-998.00K | $-942.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $9.59M | $9.61M | $12.25M | $9.28M | $8.12M | $9.45M | $9.75M | $9.44M | $8.72M | $8.78M | $8.42M | $7.08M | $6.92M | $6.92M | $5.10M | $3.68M | $2.90M | $2.02M | $1.42M | $1.61M |
| Other Expenses | $- | $- | $-1.10M | $-66.00K | $-67.00K | $-49.00K | $-62.00K | $-51.00K | $-50.00K | $-49.00K | $-91.00K | $-67.00K | $504.00K | $-74.00K | $-61.00K | $1.56M | $5.02M | $517.00K | $1.72M | $-8.00K |
| Operating Expenses | $35.71M | $37.24M | $44.18M | $37.85M | $32.93M | $34.66M | $35.97M | $37.02M | $38.08M | $36.96M | $35.91M | $34.51M | $31.05M | $26.87M | $22.70M | $15.93M | $12.97M | $11.09M | $7.28M | $6.17M |
| Cost and Expenses | $35.71M | $37.24M | $67.78M | $38.85M | $33.87M | $34.66M | $35.97M | $37.02M | $38.08M | $36.96M | $35.91M | $34.51M | $31.05M | $26.87M | $22.70M | $15.93M | $12.97M | $11.09M | $7.28M | $6.17M |
| Interest Income | $5.28M | $5.87M | $5.04M | $3.90M | $4.24M | $4.35M | $4.25M | $3.88M | $2.88M | $1.52M | $388.00K | $114.00K | $80.00K | $49.00K | $31.00K | $30.00K | $43.00K | $38.00K | $70.00K | $185.00K |
| Interest Expense | $- | $- | $- | $- | $3.83M | $- | $- | $- | $- | $1.52M | $388.00K | $114.00K | $- | $- | $- | $30.00K | $43.00K | $- | $- | $185.00K |
| Depreciation and Amortization | $832.00K | $842.00K | $1.10M | $998.00K | $942.00K | $941.00K | $955.00K | $894.00K | $933.00K | $771.00K | $534.00K | $403.00K | $320.00K | $191.00K | $169.00K | $149.00K | $146.00K | $139.00K | $134.00K | $121.00K |
| EBITDA | $-34.88M | $-36.40M | $-44.15M | $-37.85M | $-32.93M | $-33.72M | $-35.02M | $-36.13M | $-39.34M | $-36.19M | $-35.37M | $-34.10M | $-30.73M | $-26.68M | $-22.53M | $-15.78M | $-12.82M | $-10.95M | $-7.15M | $-6.04M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -590.14% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-35.71M | $-37.24M | $-45.28M | $-38.85M | $-33.87M | $-34.66M | $-35.97M | $-37.02M | $60.99M | $-36.96M | $-35.91M | $-36.51M | $-31.05M | $-46.04M | $-28.18M | $-19.61M | $-66.97M | $-11.16M | $-7.28M | $-23.84M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -607.03% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $3.48M | $6.04M | $-17.92M | $3.83M | $4.17M | $4.30M | $4.19M | $3.83M | $2.83M | $1.47M | $297.00K | $47.00K | $584.00K | $-25.00K | $-30.00K | $1.59M | $-48.93M | $555.00K | $1.79M | $177.00K |
| Income Before Tax | $-32.23M | $-31.20M | $-63.20M | $-35.02M | $-29.70M | $-30.36M | $-31.78M | $-33.20M | $-135.25M | $-35.49M | $-35.61M | $-36.46M | $-30.46M | $-46.07M | $-28.21M | $-18.02M | $-61.90M | $-10.61M | $-5.49M | $-23.66M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -532.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $954.72K | $13.36M | $-5.29M | $-4.25M | $-3.83M | $-3.17M | $-771.00K | $-297.00K | $-47.00K | $-400.00K | $19.13M | $5.46M | $3.65M | $53.96M | $37.00K | $-70.00K | $17.48M |
| Net Income | $-32.23M | $-31.20M | $-63.20M | $-35.02M | $-29.70M | $-30.36M | $-31.78M | $-29.37M | $-132.08M | $-34.72M | $-35.31M | $-36.41M | $-30.46M | $-46.07M | $-28.21M | $-18.02M | $-61.90M | $-10.61M | $-5.49M | $-23.66M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -532.28% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.01 | $-0.01 | $-0.04 | $-0.03 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $-0.13 | $-0.04 | $-0.04 | $-0.04 | $-0.03 | $-0.06 | $-0.15 | $-0.10 | $-0.34 | $-0.06 | $-0.03 | $-0.03 |
| EPS Diluted | $-0.01 | $-0.01 | $-0.04 | $-0.03 | $-0.02 | $-0.03 | $-0.03 | $-0.02 | $-0.13 | $-0.04 | $-0.04 | $-0.04 | $-0.03 | $-0.06 | $-0.15 | $-0.10 | $-0.34 | $-0.06 | $-0.03 | $-0.03 |
| Weighted Average Shares Outstanding | 2.34B | 2.26B | 1.74B | 1.21B | 1.21B | 1.20B | 1.20B | 1.20B | 1.02B | 966.39M | 961.55M | 955.93M | 950.62M | 793.02M | 188.37M | 188.37M | 183.15M | 188.37M | 188.37M | 725.55M |
| Weighted Average Shares Outstanding Diluted | 2.34B | 2.26B | 1.74B | 1.21B | 1.21B | 1.20B | 1.20B | 1.20B | 1.02B | 966.39M | 961.55M | 955.93M | 950.62M | 793.02M | 188.37M | 188.37M | 183.15M | 188.37M | 188.37M | 725.55M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $67.74M | $93.08M | $284.22M | $360.49M | $65.38M |
| Short Term Investments | $230.57M | $219.28M | $151.40M | $53.99M | $53.33M |
| Cash and Short Term Investments | $298.31M | $312.35M | $435.62M | $459.25M | $118.70M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $10.48M | $8.33M | $8.88M | $11.08M | $2.58M |
| Total Current Assets | $308.79M | $320.68M | $444.50M | $420.02M | $119.99M |
| Property Plant Equipment Net | $48.54M | $60.19M | $65.23M | $33.31M | $4.07M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $10.05M | $408.00K | $44.77M | $312.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $145.19M | $4.38M | $4.77M | $3.32M | $451.00K |
| Total Non-Current Assets | $193.73M | $74.62M | $70.41M | $81.40M | $4.83M |
| Other Assets | $- | $- | $- | $- | $-0 |
| Total Assets | $502.53M | $395.30M | $514.91M | $501.42M | $124.83M |
| Account Payables | $468.00K | $2.00M | $23.05M | $4.68M | $878.00K |
| Short Term Debt | $4.62M | $3.97M | $2.61M | $570.00K | $877.00K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $18.54M | $9.40M |
| Other Current Liabilities | $26.31M | $20.19M | $23.03M | $21.13M | $11.93M |
| Total Current Liabilities | $31.39M | $26.16M | $48.69M | $26.38M | $13.68M |
| Long Term Debt | $47.27M | $51.89M | $107.59M | $37.01M | $2.11M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $362.00K | $566.00K | $-53.22M | $-18.51M | $223.02M |
| Total Non-Current Liabilities | $47.63M | $52.45M | $54.37M | $18.51M | $225.13M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $79.03M | $78.61M | $103.06M | $44.89M | $238.81M |
| Preferred Stock | $- | $- | $- | $501.42M | $221.41M |
| Common Stock | $28.00K | $15.00K | $15.00K | $12.00K | $3.00K |
| Retained Earnings | $-767.66M | $-606.01M | $-480.97M | $-238.17M | $-115.40M |
| Accumulated Other Comprehensive Income Loss | $405.00K | $77.00K | $-1.04M | $-162.00K | $2.00K |
| Other Total Stockholders Equity | $1.19B | $922.61M | $893.85M | $193.43M | $-219.99M |
| Total Stockholders Equity | $423.50M | $316.69M | $-480.97M | $-238.17M | $-113.98M |
| Total Equity | $423.50M | $316.69M | $-480.97M | $-238.17M | $-113.98M |
| Total Liabilities and Stockholders Equity | $502.53M | $395.30M | $-377.92M | $-193.28M | $124.83M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $502.53M | $395.30M | $-377.92M | $-193.28M | $124.83M |
| Total Investments | $230.57M | $229.32M | $151.40M | $98.76M | $53.33M |
| Total Debt | $51.89M | $55.86M | $55.10M | $18.79M | $2.99M |
| Net Debt | $-15.85M | $-37.22M | $-229.12M | $-341.70M | $-62.39M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $67.74M | $68.89M | $172.80M | $76.73M | $93.08M | $112.86M | $138.79M | $272.76M | $284.22M | $219.26M | $298.01M | $333.35M | $360.49M | $445.81M | $156.40M | $169.99M | $65.38M | $-50.37M |
| Short Term Investments | $230.57M | $250.03M | $235.61M | $220.96M | $219.28M | $183.81M | $178.46M | $116.98M | $151.40M | $136.67M | $73.47M | $59.19M | $53.99M | $40.83M | $37.28M | $42.35M | $53.33M | $100.74M |
| Cash and Short Term Investments | $298.31M | $318.91M | $408.41M | $297.69M | $312.35M | $343.56M | $317.25M | $389.74M | $435.62M | $365.50M | $371.48M | $392.53M | $459.25M | $486.64M | $193.67M | $212.34M | $118.70M | $50.37M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $-47.82M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $10.48M | $11.26M | $9.59M | $8.94M | $8.33M | $9.30M | $6.61M | $8.14M | $8.88M | $19.65M | $19.89M | $21.68M | $11.08M | $11.34M | $7.24M | $4.01M | $1.29M | $- |
| Total Current Assets | $308.79M | $330.17M | $418.00M | $306.62M | $320.68M | $305.97M | $323.85M | $397.88M | $444.50M | $365.75M | $381.42M | $403.37M | $420.02M | $492.31M | $197.29M | $214.34M | $119.99M | $50.37M |
| Property Plant Equipment Net | $48.54M | $50.04M | $51.54M | $58.53M | $60.19M | $61.75M | $63.08M | $64.42M | $65.23M | $65.93M | $38.97M | $37.34M | $33.31M | $27.56M | $4.13M | $3.80M | $4.07M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $142.16M | $144.39M | $52.24M | $408.00K | $10.05M | $46.89M | $48.08M | $408.00K | $408.00K | $9.57M | $19.31M | $29.22M | $44.77M | $408.00K | $5.00M | $5.00M | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $3.03M | $4.29M | $3.96M | $4.46M | $4.38M | $4.80M | $5.66M | $4.84M | $4.77M | $5.18M | $5.12M | $5.53M | $3.32M | $1.67M | $3.96M | $1.49M | $763.00K | $-50.37M |
| Total Non-Current Assets | $193.73M | $198.72M | $107.74M | $63.40M | $74.62M | $113.44M | $116.81M | $69.66M | $70.41M | $80.68M | $63.40M | $72.09M | $81.40M | $29.64M | $13.09M | $10.28M | $4.83M | $-50.37M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $502.53M | $528.90M | $525.74M | $370.02M | $395.30M | $419.41M | $440.66M | $467.54M | $514.91M | $446.43M | $444.82M | $475.47M | $501.42M | $521.95M | $210.38M | $224.63M | $124.83M | $- |
| Account Payables | $468.00K | $2.40M | $2.14M | $2.63M | $2.00M | $3.70M | $2.63M | $3.35M | $23.05M | $4.32M | $2.29M | $4.71M | $4.68M | $1.32M | $1.51M | $1.04M | $878.00K | $- |
| Short Term Debt | $4.62M | $4.45M | $8.57M | $4.13M | $7.94M | $7.64M | $7.34M | $6.24M | $1.30M | $2.06M | $402.00K | $28.00K | $285.00K | $1.73M | $1.78M | $898.00K | $877.00K | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $1.73M | $- | $- | $18.58M | $16.19M | $- | $- | $- | $- | $- | $18.54M | $14.34M | $12.29M | $5.87M | $9.40M | $- |
| Other Current Liabilities | $26.31M | $23.17M | $14.18M | $23.48M | $16.22M | $15.39M | $13.32M | $15.93M | $24.34M | $21.30M | $19.63M | $16.65M | $21.42M | $16.54M | $14.63M | $9.27M | $11.93M | $- |
| Total Current Liabilities | $31.39M | $30.02M | $24.89M | $30.24M | $26.16M | $26.73M | $23.29M | $25.52M | $48.69M | $27.68M | $22.32M | $21.39M | $26.38M | $19.59M | $17.91M | $11.21M | $13.68M | $- |
| Long Term Debt | $47.27M | $48.49M | $49.68M | $50.81M | $103.78M | $105.88M | $107.94M | $109.87M | $53.79M | $106.86M | $54.87M | $58.83M | $18.51M | $38.74M | $3.34M | $1.88M | $2.11M | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $362.00K | $340.00K | $82.00K | $559.00K | $-51.32M | $-52.18M | $-53.27M | $-54.31M | $573.00K | $-53.43M | $-27.44M | $-29.42M | $- | $-19.37M | $339.13M | $340.80M | $223.02M | $- |
| Total Non-Current Liabilities | $47.63M | $48.83M | $49.76M | $51.37M | $52.45M | $53.70M | $54.66M | $55.57M | $54.37M | $53.43M | $27.44M | $29.42M | $18.51M | $19.37M | $342.47M | $342.67M | $225.13M | $- |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $79.03M | $78.85M | $74.66M | $81.61M | $78.61M | $80.43M | $77.96M | $81.09M | $103.06M | $81.11M | $49.76M | $50.81M | $44.89M | $38.96M | $360.38M | $353.89M | $238.81M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $521.95M | $340.80M | $340.80M | $223.02M | $63.40M |
| Common Stock | $28.00K | $28.00K | $27.00K | $15.00K | $15.00K | $15.00K | $15.00K | $15.00K | $15.00K | $12.00K | $12.00K | $12.00K | $12.00K | $12.00K | $3.00K | $3.00K | $3.00K | $- |
| Retained Earnings | $-767.66M | $-735.43M | $-704.23M | $-641.03M | $-606.01M | $-576.31M | $-545.95M | $-514.17M | $-480.97M | $-345.72M | $-310.23M | $-274.62M | $-238.17M | $-207.70M | $-161.63M | $-133.42M | $-115.40M | $- |
| Accumulated Other Comprehensive Income Loss | $405.00K | $1.82M | $-196.00K | $-210.00K | $77.00K | $-575.00K | $-793.00K | $-514.00K | $-1.04M | $-1.38M | $-1.22M | $-951.00K | $-162.00K | $-521.95M | $-1.00K | $1.00K | $2.00K | $-13.60M |
| Other Total Stockholders Equity | $1.19B | $1.18B | $1.16B | $929.63M | $922.61M | $915.85M | $909.43M | $901.12M | $893.85M | $712.41M | $706.51M | $700.23M | $694.84M | $168.73M | $11.63M | $-336.64M | $-221.61M | $- |
| Total Stockholders Equity | $423.50M | $450.04M | $451.09M | $288.41M | $316.69M | $-576.31M | $362.70M | $-514.17M | $-480.97M | $-345.72M | $395.07M | $424.66M | $456.53M | $482.99M | $-150.00M | $-129.26M | $-113.98M | $49.80M |
| Total Equity | $423.50M | $450.04M | $451.09M | $288.41M | $316.69M | $-576.31M | $362.70M | $-514.17M | $-480.97M | $-345.72M | $395.07M | $424.66M | $456.53M | $482.99M | $-150.00M | $-129.26M | $-113.98M | $49.80M |
| Total Liabilities and Stockholders Equity | $502.53M | $528.90M | $525.74M | $370.02M | $395.30M | $-495.88M | $440.66M | $-433.08M | $-377.92M | $-264.61M | $444.82M | $475.47M | $501.42M | $521.95M | $210.38M | $224.63M | $124.83M | $49.80M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $502.53M | $528.90M | $525.74M | $370.02M | $395.30M | $-495.88M | $440.66M | $-433.08M | $-377.92M | $-264.61M | $444.82M | $475.47M | $501.42M | $521.95M | $210.38M | $224.63M | $124.83M | $49.80M |
| Total Investments | $372.73M | $394.42M | $287.85M | $221.37M | $229.32M | $230.70M | $226.54M | $116.98M | $151.40M | $146.24M | $92.78M | $88.41M | $53.99M | $40.83M | $42.28M | $47.35M | $53.33M | $100.74M |
| Total Debt | $51.89M | $52.94M | $53.97M | $61.84M | $55.86M | $56.76M | $57.64M | $58.05M | $55.10M | $54.46M | $27.64M | $29.43M | $18.79M | $20.23M | $2.56M | $2.77M | $2.99M | $- |
| Net Debt | $-15.85M | $-15.95M | $-118.83M | $-14.88M | $-37.22M | $-56.10M | $-81.15M | $-214.70M | $-229.12M | $-164.80M | $-270.37M | $-303.92M | $-341.70M | $-425.58M | $-153.84M | $-167.22M | $-62.39M | $50.37M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-161.65M | $-125.04M | $-242.81M | $-122.76M | $-101.66M |
| Depreciation and Amortization | $3.81M | $3.73M | $2.64M | $829.00K | $540.00K |
| Deferred Income Tax | $- | $- | $- | $-1.51M | $-7.39M |
| Stock Based Compensation | $26.97M | $26.23M | $20.11M | $8.33M | $797.00K |
| Change in Working Capital | $1.74M | $813.00K | $15.79M | $7.71M | $3.29M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.53M | $-886.00K | $676.00K | $1.34M | $-380.00K |
| Other Working Capital | $3.27M | $1.70M | $15.11M | $6.36M | $3.67M |
| Other Non Cash Items | $19.72M | $-6.95M | $101.01M | $27.81M | $71.75M |
| Net Cash Provided by Operating Activities | $-109.42M | $-101.22M | $-103.26M | $-79.60M | $-32.69M |
| Investments in Property Plant and Equipment | $-60.00K | $-1.77M | $-16.55M | $-18.89M | $-38.69M |
| Acquisitions Net | $- | $- | $4.00M | $7.68M | $37.74M |
| Purchases of Investments | $-403.22M | $-314.39M | $-134.33M | $-105.81M | $-99.20M |
| Sales Maturities of Investments | $269.32M | $244.94M | $79.80M | $60.11M | $66.69M |
| Other Investing Activities | $-22.66M | $-20.00M | $-4.00M | $-7.68M | $-37.74M |
| Net Cash Used for Investing Activities | $-156.62M | $-91.22M | $-71.08M | $-64.59M | $-71.20M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $239.06M | $1.29M | $95.25M | $317.00M | $139.99M |
| Common Stock Repurchased | $800.00K | $790.00K | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $1.64M | $1.29M | $2.82M | $122.40M | $139.99M |
| Net Cash Used Provided by Financing Activities | $240.70M | $1.29M | $98.08M | $439.40M | $139.99M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-25.34M | $-191.14M | $-76.27M | $295.21M | $36.10M |
| Cash at End of Period | $68.15M | $93.48M | $284.62M | $360.89M | $65.69M |
| Cash at Beginning of Period | $93.48M | $284.62M | $360.89M | $65.69M | $29.58M |
| Operating Cash Flow | $-109.42M | $-101.22M | $-103.26M | $-79.60M | $-32.69M |
| Capital Expenditure | $-60.00K | $-1.77M | $-16.55M | $-18.89M | $-38.69M |
| Free Cash Flow | $-109.48M | $-102.99M | $-119.81M | $-98.48M | $-71.38M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-32.23M | $-31.20M | $-63.20M | $-35.02M | $-29.70M | $-30.36M | $-31.78M | $-33.20M | $-135.25M | $-35.49M | $-35.61M | $-36.46M | $-30.46M | $-46.07M | $-28.21M | $-18.02M | $-61.90M | $-10.61M | $-5.49M | $-23.66M |
| Depreciation and Amortization | $832.00K | $875.00K | $1.13M | $998.00K | $942.00K | $941.00K | $955.00K | $894.00K | $933.00K | $771.00K | $534.00K | $403.00K | $320.00K | $191.00K | $169.00K | $149.00K | $146.00K | $139.00K | $134.00K | $121.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-9.68M | $- | $- | $- | $- | $- | $- | $- | $33.00K | $29.00K | $33.00K | $-1.60M | $-5.05M | $-571.00K | $- | $-16.00K |
| Stock Based Compensation | $6.31M | $6.64M | $7.18M | $6.85M | $6.14M | $6.24M | $7.01M | $6.84M | $5.38M | $5.23M | $5.05M | $4.44M | $2.88M | $3.02M | $1.64M | $795.00K | $407.00K | $176.00K | $109.00K | $105.00K |
| Change in Working Capital | $1.13M | $3.21M | $527.00K | $-3.74M | $30.00K | $1.43M | $-726.00K | $77.00K | $3.39M | $5.71M | $2.89M | $3.79M | $5.29M | $436.00K | $2.65M | $-671.00K | $-698.00K | $3.31M | $503.00K | $168.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-1.94M | $482.00K | $-710.00K | $633.00K | $-1.66M | $1.03M | $-701.00K | $446.00K | $-864.00K | $1.53M | $-1.88M | $1.90M | $935.00K | $-171.00K | $405.00K | $175.00K | $-1.39M | $1.53M | $-212.00K | $-309.00K |
| Other Working Capital | $3.06M | $2.73M | $1.24M | $-4.37M | $1.69M | $400.00K | $-25.00K | $-369.00K | $4.25M | $4.19M | $4.77M | $1.89M | $4.35M | $607.00K | $2.25M | $-846.00K | $694.00K | $1.78M | $715.00K | $477.00K |
| Other Non Cash Items | $-598.00K | $-1.94M | $25.18M | $5.87M | $7.49M | $-2.37M | $-1.41M | $-975.00K | $99.17M | $-174.00K | $-12.00K | $2.02M | $-539.00K | $19.18M | $5.49M | $3.68M | $54.00M | $75.00K | $-1.76M | $17.67M |
| Net Cash Provided by Operating Activities | $-24.56M | $-22.42M | $-29.18M | $-33.25M | $-24.79M | $-24.12M | $-25.95M | $-26.36M | $-26.37M | $-23.95M | $-27.14M | $-25.81M | $-22.48M | $-23.22M | $-18.23M | $-15.67M | $-13.10M | $-7.48M | $-6.50M | $-5.61M |
| Investments in Property Plant and Equipment | $- | $-5.00K | $-13.00K | $-42.00K | $-82.00K | $-240.00K | $-247.00K | $-21.21M | $-864.00K | $-1.79M | $-4.56M | $-9.34M | $-5.83M | $-6.35M | $-579.00K | $-6.12M | $-20.02M | $-224.00K | $-11.88M | $-6.56M |
| Acquisitions Net | $- | $- | $- | $- | $-4.63K | $1.57K | $108.42K | $20.00M | $4.00K | $53.44K | $4.63K | $4.00M | $7.68M | $1.68M | $6.00M | $6.00M | $20.00M | $75.00K | $11.67M | $- |
| Purchases of Investments | $-67.13M | $-191.76M | $-100.35M | $-43.99M | $-61.12M | $-53.82M | $-175.17M | $-24.28M | $-37.90M | $-72.14M | $-12.53M | $-11.76M | $-64.12M | $-9.79M | $-9.92M | $-21.99M | $-1.81M | $-57.42M | $-39.97M | $- |
| Sales Maturities of Investments | $89.75M | $89.33M | $36.25M | $54.00M | $65.75M | $52.25M | $66.75M | $60.20M | $33.90M | $18.70M | $7.90M | $19.30M | $6.00M | $11.20M | $14.96M | $27.95M | $38.40M | $8.50M | $12.24M | $7.55M |
| Other Investing Activities | $- | $-157.00K | $-22.50M | $10.01M | $4.63K | $-1.57K | $-108.42K | $-20.00M | $-4.00K | $-53.44K | $-4.63K | $-4.00M | $-7.68M | $-1.68M | $-6.00M | $-6.00M | $-20.00M | $-75.00K | $-11.67M | $1.55M |
| Net Cash Used for Investing Activities | $22.62M | $-102.59M | $-86.61M | $9.97M | $4.54M | $-1.81M | $-108.67M | $14.71M | $-4.87M | $-55.23M | $-9.19M | $-1.79M | $-63.95M | $-4.94M | $4.46M | $-162.00K | $16.57M | $-49.15M | $-39.61M | $992.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $20.79M | $211.37M | $6.91M | $456.00K | $7.00K | $649.00K | $183.00K | $95.25M | $427.00K | $992.00K | $460.00K | $1.11M | $317.57M | $180.00K | $120.54M | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $395.00K | $- | $- | $790.00K | $- | $- | $- | $- | $- | $- | $- | $1.07M | $- | $- | $- | $-112.00K | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $801.00K | $311.00K | $500.00K | $24.00K | $456.00K | $7.00K | $649.00K | $183.00K | $945.00K | $427.00K | $992.00K | $460.00K | $1.11M | $317.57M | $180.00K | $120.54M | $-111.00K | $14.61M | $125.00M | $490.00K |
| Net Cash Used Provided by Financing Activities | $801.00K | $21.10M | $211.87M | $6.93M | $456.00K | $7.00K | $649.00K | $183.00K | $96.20M | $427.00K | $992.00K | $460.00K | $1.11M | $317.57M | $180.00K | $120.54M | $-111.00K | $14.61M | $125.00M | $490.00K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-146.72M | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-1.15M | $-103.92M | $96.08M | $-16.35M | $-19.79M | $-25.93M | $-133.97M | $-11.46M | $64.96M | $-78.75M | $-35.34M | $-27.14M | $-85.32M | $289.42M | $-13.59M | $104.71M | $3.36M | $-42.01M | $78.88M | $-4.13M |
| Cash at End of Period | $68.15M | $69.29M | $172.80M | $76.73M | $93.08M | $113.27M | $139.19M | $273.16M | $284.62M | $219.67M | $298.42M | $333.75M | $360.89M | $446.22M | $156.80M | $170.40M | $65.69M | $62.33M | $104.34M | $25.45M |
| Cash at Beginning of Period | $69.29M | $173.21M | $76.73M | $93.08M | $112.86M | $139.19M | $273.16M | $284.62M | $219.67M | $298.42M | $333.75M | $360.89M | $446.22M | $156.80M | $170.40M | $65.69M | $62.33M | $104.34M | $25.45M | $29.58M |
| Operating Cash Flow | $-24.56M | $-22.42M | $-29.18M | $-33.25M | $-24.79M | $-24.12M | $-25.95M | $-26.36M | $-26.37M | $-23.95M | $-27.14M | $-25.81M | $-22.48M | $-23.22M | $-18.23M | $-15.67M | $-13.10M | $-7.48M | $-6.50M | $-5.61M |
| Capital Expenditure | $- | $-5.00K | $-13.00K | $-42.00K | $-82.00K | $-240.00K | $-247.00K | $-21.21M | $-864.00K | $-1.79M | $-4.56M | $-9.34M | $-5.83M | $-6.35M | $-579.00K | $-6.12M | $-20.02M | $-224.00K | $-11.88M | $-6.56M |
| Free Cash Flow | $-24.56M | $-22.42M | $-29.20M | $-33.29M | $-24.87M | $-24.36M | $-26.20M | $-47.56M | $-27.24M | $-25.74M | $-31.70M | $-35.14M | $-28.31M | $-29.57M | $-18.81M | $-21.79M | $-33.12M | $-7.70M | $-18.39M | $-12.17M |
Erasca Dividends
Explore Erasca's dividend history, including dividend yield, payout ratio, and historical payments.
Erasca News
Read the latest news about Erasca, including recent articles, headlines, and updates.
Erasca Announces Three Poster Presentations at the 2025 AACR Annual Meeting
Presentations will feature potential best-in-class pan-RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the RAS/MAPK pathway SAN DIEGO, March 25, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the company will present three poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 25 - 30, 2025, in Chicago, Illinois. The abstracts will be available on the AACR 2025 meeting website.
Erasca to Present at the Guggenheim Securities SMID Cap Biotech Conference
SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Guggenheim Securities SMID Cap Biotech Conference being held at the Lotte New York Palace in New York, New York. Management will participate in a fireside chat on Thursday, February 6, 2025, at 9:30 am Eastern Time and will also participate in one-on-one investor meetings.
Erasca's Naporafenib Is Shaping Up Nicely For NRASm Melanoma
Naporafenib is Erasca's main candidate, and it has Fast Track status for NRASm melanoma. I see the company has a robust balance sheet, with roughly $463.3 million in cash and equivalents as of Q3, 2024. They estimate a runway into 2H2027. SEACRAFT-1 already showed that Naporafenib has potentially better efficacy compared to the SoC and competitors.
Down -25.4% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -27.17% in 4 Weeks, Here's Why Erasca (ERAS) Looks Ripe for a Turnaround
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Down -24.08% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Down -22.89% in 4 Weeks, Here's Why You Should You Buy the Dip in Erasca (ERAS)
Erasca (ERAS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Erasca (ERAS) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Erasca (ERAS), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Erasca to Present at Upcoming Investor Conferences
SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in the following investor conferences and will also participate in one-on-one investor meetings.
Should You Buy Erasca, Inc. (ERAS) After Golden Cross?
After reaching an important support level, Erasca, Inc. (ERAS) could be a good stock pick from a technical perspective. ERAS recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.
Erasca to Present at Upcoming Investor Conferences in June
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that Jonathan E. Lim, M.D., chairman, CEO, and co-founder, and David M. Chacko, M.D., chief financial officer and chief business officer, will participate in the following investor conferences in June 2024, and will also participate in one-on-one investor meetings.
Erasca Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
SAN DIEGO, May 21, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the closing of an oversubscribed underwritten offering of 99,459,458 shares of its common stock, at a price of $1.85 per share, which includes the exercise in full by the underwriters of their option to purchase 12,972,972 additional shares. All of the shares in the offering were sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, were approximately $184.0 million.
Week In Review: Takeda Options Alzheimer's Therapy From AC Immune In $2.2 Billion Deal
SolStock Deals and Financings Japan’s Takeda (TAK, OTCPK:TKPHF; TSE: 4502) acquired global rights to an Alzheimer’s therapy developed by AC Immune SA (ACIU) of Switzerland for $100 million upfront and up to $2.1 billion in milestone payments (see story). With the $100 million, Takeda owns an option to license AC Immune’s active immunotherapies that target toxic forms of amyloid beta (Abeta), including ACI-24.060. ACI-24.060 is an anti-Abeta active immunotherapy candidate aimed at reducing the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s disease progression. Currently, ACI-24.060 is being tested in a double-blind, placebo-controlled Phase Ib/II trial in subjects with mild Alzheimer’s disease and in adults with Down's syndrome. San Diego’s Erasca (ERAS) acquired rights for two China-developed pre-clinical RAS candidates in two separate agreements, while it is sidelining two of its own candidates and temporarily discontinuing development on a third candidate. Erasca will also raise $160 million from investors. The company acquired ex-China rights to a pan-RAS molecular glue (ERAS-0015) from Joyo Pharmatech of Guangzhou in a $189 million deal and global rights to a pan-KRAS inhibitor (ERAS-4001) from Sichuan Medshine Discovery in a $170 million agreement. Shenzhen Beimei Pharma acquired greater China rights for Twyneo, a therapy for acne vulgaris, from Israel’s Sol-Gel (SLGL) for $15 million. Sol-Gel will be eligible to receive up to $10 million in upfront and regulator milestones. The remaining $5 million is potential royalty payments. Twyneo is the only fixed-dose combination of tretinoin and benzoyl peroxide cream available in the US; it is approved to treat acne vulgaris in adults and pediatric patients. Beimei markets products for pediatrics patients with a portfolio of more than 40 drugs approved or in the pipeline. Trials and Approvals Shanghai’s Zai Lab (ZLAB; HK: 9688) reported China’s NMPA approved Augtyro (repotrectinib) as a treatment for adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) (see story). The approval is based on an open-label, single-arm, Phase I/II trial that evaluated repotrectinib in TKI-naïve and TKI-pretreated patients with ROS1-positive NSCLC. In 2020, Zai Lab acquired China rights to the drug from Turning Point Therapeutics of San Diego for $25 million upfront and up to $151 million in milestones, plus royalties. Turning Point is now a division of Bristol-Myers Squibb (BMY). Shanghai Everest Medicines (HK: 1952) launched Nefecon, a treatment for IgA nephropathy (IgAN), in China by filling the first prescription. IgAN, a rare disease that accounts for 35-50% of glomerular disease cases in China, can cause end-stage renal disease that is treated by kidney replacement or dialysis. Nefecon is a targeted-release formulation of budesonide, a second-generation synthetic corticosteroid. In 2019, Everest acquired greater China rights to the drug from Calliditas Therapeutics (CALT, OTCPK:CLTEF) of Sweden in a $121 million agreement. Nefecon is already approved in the US and EU. Suzhou Ractigen Therapeutics reported that a China IND was approved for RAG-17 as a therapy for Amyotrophic Lateral Sclerosis (ALS). RAG-17 is a therapeutic siRNA designed to suppress the SOD1 gene in ALS patients with pathogenic mutations. Of the more than 50 genes associated with ALS, SOD1 gene mutations account for approximately 20% of the cases. Using Ractigen's proprietary SCAD delivery platform, RAG-17 combines siRNA with an accessory oligonucleotide to improve efficacy in central nervous system tissues. In preclinical studies, RAG-17 showed the ability to improve motor function and prolong survival. Beijing InnoCare Pharma (OTCPK:INCPF; HK: 09969; SHA: 688428) has completed the enrollment process in a China Phase II trial of ICP-488, a potential psoriasis therapy (see story). ICP-488 is a TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor. The trial enrolled 129 patients who were randomized to one of three treatment groups in a 1:1:1 ratio: a 6mg once-daily group, a 9mg once-daily group, and a placebo group, for 12 consecutive weeks of treatment. By binding the JH2 domain, ICP-488 blocks the signal transduction of IL-23, IL-12, type 1 IFN and other inflammatory cytokines. Shanghai Mabwell (SHA: 688062) reported positive data from a China trial of its novel Nectin-4-targeting ADC for triple-negative breast cancer. In 20 patients with advanced or metastatic disease, 50% reported an objective response and 80% experienced disease control. One patient had a complete response that has continued for 20 months so far. Mabwell says a China IND for the drug, 9MW2821, has also been accepted in combination with an immune checkpoint inhibitor. According to the company, 9MW2821 is the first the Nectin-4-targeting ADC developed by a Chinese company to start clinical trials. Nanjing IASO Bio announced that Science Immunology, a sub-journal of Science, published a single-cell analysis of its anti-BCMA CAR T cell therapy in patients with neuromyelitis optica spectrum disorder (NMOSD). NMOSD is an autoimmune disease that usually occurs in the optic nerve and spinal cord, though it can affect the brain. The disease, which occurs in flare-ups that can cause muscle weakness or blindness, is sometimes misdiagnosed as multiple myeloma. Last year, IASO and its partner, Innovent (OTCPK:IVBIY, OTCPK:IVBXF), were approved in China to launch Equecabtagene Autoleucel, an anti-BCMA CAR T drug, as a fourth-line therapy for multiple myeloma. Original Post Editor's Note: The summary bullets for this article were chosen by Seeking Alpha editors.
Erasca Announces Pricing of Underwritten Offering of Common Stock
SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 86,486,486 shares of its common stock at a price of $1.85 per share. All of the shares to be sold in the offering are to be sold by Erasca. The gross proceeds to Erasca from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $160 million. In addition, Erasca has granted the underwriters a 30-day option to purchase up to an additional 12,972,972 shares of common stock at the offering price. The offering is expected to close on May 21, 2024, subject to the satisfaction of customary closing conditions.
Erasca Reports First Quarter 2024 Business Updates and Financial Results
Median OS of 13-14 months for naporafenib plus trametinib in pooled analysis of patients with NRASm melanoma Strengthened balance sheet with private placement financing from high-quality new and existing healthcare-focused investors Pro forma cash, cash equivalents, and marketable securities of $334 million is expected to fund operations into H2 2026 SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2024. “We started 2024 strong with compelling survival data from a pooled analysis of mature data for naporafenib plus trametinib in patients with NRAS-mutant (NRASm) melanoma, which showed a near doubling of median overall survival (mOS) versus comparable historical controls,” said Jonathan E.
Erasca to Present at the Bank of America Health Care Conference
SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the Bank of America Health Care Conference being held at the Encore Hotel in Las Vegas, Nevada. Management will present on Wednesday, May 15, 2024 at 4:20 pm Pacific Time and will also participate in one-on-one investor meetings.
Erasca to Present at the 42nd Annual J.P. Morgan Healthcare Conference
SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced its participation in the 42nd annual J.P. Morgan Healthcare Conference being held at the Westin St. Francis Hotel in San Francisco, California. Jonathan E. Lim, M.D., chairman, CEO, and co-founder, will present an overview of the company on Tuesday, January 9, 2024 at 9:00 am Pacific Time in Elizabethan Room D. Dr. Lim and David M. Chacko, M.D., chief financial officer and chief business officer, will also participate in one-on-one investor meetings.
Erasca Granted FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma
First-in-class and best-in-class potential in NRAS-mutated melanoma and other RAS/MAPK pathway-altered solid tumors Naporafenib has been dosed in more than 500 patients to date, establishing its safety, tolerability, and preliminary proof-of-concept in multiple indications Pivotal Phase 3 SEACRAFT-2 trial initiation in NRAS-mutated melanoma on track for H1 2024 SAN DIEGO, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that the United States Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to naporafenib in combination with trametinib (MEKINIST®) for the treatment of adult patients with unresectable or metastatic melanoma who have progressed on, or are intolerant to, an anti‑programmed death-1 (ligand 1) (PD‑(L)1)-based regimen, and whose tumors contain an NRAS mutation (NRASm). Naporafenib is an orally available, Phase 3-ready pan-RAF inhibitor with a potential first-in-class and best-in-class profile in NRASm melanoma and other RAS/MAPK pathway-altered solid tumors.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ERAS.